News

FRAXA Supporting Work Into Drug Repurposing to Treat Depression

The FRAXA Research Foundation is supporting a project to identify available medicines that might be repurposed to treat major depressive disorder (MDD) in people with fragile X syndrome. Depression occurs frequently among people with autism spectrum disorders (ASD), of which fragile X is the most common genetic cause.

FDA OKs Phase 2 Trial Design for Xanamem

The U.S. Food and Drug Administration (FDA) has given positive feedback to Actinogen’s pre-investigational new drug (pre-IND) submission regarding Xanamem, its experimental oral therapy for fragile X syndrome. In a written response following a pre-IND meeting with Actinogen, the FDA agreed the data gathered and the proposed trial design…

Events Local and Global Marking July, Fragile X Awareness Month

From posting yard signs to swapping out exterior lighting, people across the U.S. are poised to mark Fragile X Awareness Month, observed each July. A global day — July 22 — is also set aside, with illuminations worldwide helping to call attention to the genetic disorder. Awareness and education…

EveryLife Introduces First of Kind ‘Roadmap’ to ICD Codes

To help patient advocacy leaders and their partners better understand how global health statistics codes — known as ICD codes — are assigned, updated, and revised in the U.S. health information system, the EveryLife Foundation for Rare Diseases is presenting a first-of-its-kind resource guide. The foundation created the…